415 related articles for article (PubMed ID: 34220791)
1. Investigation of Genetic Determinants of Glioma Immune Phenotype by Integrative Immunogenomic Scale Analysis.
Zhao B; Wang Y; Wang Y; Dai C; Wang Y; Ma W
Front Immunol; 2021; 12():557994. PubMed ID: 34220791
[TBL] [Abstract][Full Text] [Related]
2. A novel immune cell signature for predicting glioblastoma after radiotherapy prognosis and guiding therapy.
Huang R; Lu X; Sun X; Wu H
Int J Immunopathol Pharmacol; 2024; 38():3946320241249395. PubMed ID: 38687369
[No Abstract] [Full Text] [Related]
3. Higher cytolytic score correlates with an immunosuppressive tumor microenvironment and reduced survival in glioblastoma.
Haddad AF; Chen JS; Oh T; Pereira MP; Joshi RS; Aghi MK
Sci Rep; 2020 Oct; 10(1):17580. PubMed ID: 33067480
[TBL] [Abstract][Full Text] [Related]
4. Identification of three tumor antigens and immune subtypes for mRNA vaccine development in diffuse glioma.
Zhou Q; Yan X; Zhu H; Xin Z; Zhao J; Shen W; Yin W; Guo Y; Xu H; Zhao M; Liu W; Jiang X; Ren C
Theranostics; 2021; 11(20):9775-9790. PubMed ID: 34815785
[No Abstract] [Full Text] [Related]
5. [Single-cell transcriptome analysis of multigrade glioma heterogeneity and immune microenvironment revealed potential prognostic biomarkers].
Liu J; Xu K; Ma L; Wang Y
Sheng Wu Gong Cheng Xue Bao; 2022 Oct; 38(10):3790-3808. PubMed ID: 36305410
[TBL] [Abstract][Full Text] [Related]
6. The levels of immunosuppressive checkpoint protein PD-L1 and tumor-infiltrating lymphocytes were integrated to reveal the glioma tumor microenvironment.
Zhang W; Liu L; Liu X; Han C; Li Q
Environ Toxicol; 2024 Feb; 39(2):815-829. PubMed ID: 37792606
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive analysis of m
Zhao K; Li W; Yang Y; Hu X; Dai Y; Huang M; Luo J; Zhang K; Zhao N
Front Immunol; 2022; 13():955848. PubMed ID: 36203569
[TBL] [Abstract][Full Text] [Related]
8. A novel pyroptosis-related gene signature predicts the prognosis of glioma through immune infiltration.
Zhang M; Cheng Y; Xue Z; Sun Q; Zhang J
BMC Cancer; 2021 Dec; 21(1):1311. PubMed ID: 34876094
[TBL] [Abstract][Full Text] [Related]
9. Classification of Glioblastoma Associated with Immune Checkpoints and Tumor Microenvironment based on Immunogenomic Profiling.
Zheng P; Zhang X; Ren D; Bai Q
Neurol India; 2024 Mar; 72(2):297-303. PubMed ID: 38691473
[TBL] [Abstract][Full Text] [Related]
10. Identification and validation of a risk signature based on extracellular matrix-related genes in gliomas.
Liu J; Li G
Medicine (Baltimore); 2021 Apr; 100(16):e25603. PubMed ID: 33879726
[TBL] [Abstract][Full Text] [Related]
11. ABCD3 is a prognostic biomarker for glioma and associated with immune infiltration: A study based on oncolysis of gliomas.
Li J; Zhang Y; Qu Z; Ding R; Yin X
Front Cell Infect Microbiol; 2022; 12():956801. PubMed ID: 35959373
[TBL] [Abstract][Full Text] [Related]
12. Grade scoring system reveals distinct molecular subtypes and identifies KIF20A as a novel biomarker for predicting temozolomide treatment efficiency in gliomas.
Ye L; Tong S; Wang Y; Wang Y; Ma W
J Cancer Res Clin Oncol; 2023 Sep; 149(12):9857-9876. PubMed ID: 37248320
[TBL] [Abstract][Full Text] [Related]
13. Cancer-associated fibroblast-associated gene IGFBP2 promotes glioma progression through induction of M2 macrophage polarization.
Zhang X; Sun X; Guo C; Li J; Liang G
Am J Physiol Cell Physiol; 2024 Jan; 326(1):C252-C268. PubMed ID: 37982173
[TBL] [Abstract][Full Text] [Related]
14. ITGB2 as a prognostic indicator and a predictive marker for immunotherapy in gliomas.
Xu H; Zhang A; Han X; Li Y; Zhang Z; Song L; Wang W; Lou M
Cancer Immunol Immunother; 2022 Mar; 71(3):645-660. PubMed ID: 34313821
[TBL] [Abstract][Full Text] [Related]
15. A pyroptosis-related signature predicts prognosis and indicates immune microenvironment infiltration in glioma.
Chen J; Chen S; Li B; Zhou S; Lin H
Cancer Med; 2023 Feb; 12(4):5071-5087. PubMed ID: 36161280
[TBL] [Abstract][Full Text] [Related]
16. Identification of INSRR as an immune-related gene in the tumor microenvironment of glioblastoma by integrated bioinformatics analysis.
Zhang H; Bao M; Liao D; Zhang Z; Tian Z; Yang E; Luo P; Jiang X
Med Oncol; 2023 Apr; 40(6):161. PubMed ID: 37099121
[TBL] [Abstract][Full Text] [Related]
17. Pyroptosis: a novel signature to predict prognosis and immunotherapy response in gliomas.
He G; Chen Z; Zhuo S; Tang J; Hao W; Yang K; Yang C
Hum Cell; 2022 Nov; 35(6):1976-1992. PubMed ID: 36129672
[TBL] [Abstract][Full Text] [Related]
18. Transcriptional expression of ZICs as an independent indicator of survival in gliomas.
Han Z; Jia J; Lv Y; Wang R; Cao K
Sci Rep; 2021 Sep; 11(1):17532. PubMed ID: 34475426
[TBL] [Abstract][Full Text] [Related]
19. Classification of diffuse lower-grade glioma based on immunological profiling.
Wu F; Wang ZL; Wang KY; Li GZ; Chai RC; Liu YQ; Jiang HY; Zhai Y; Feng YM; Zhao Z; Zhang W
Mol Oncol; 2020 Sep; 14(9):2081-2095. PubMed ID: 32392361
[TBL] [Abstract][Full Text] [Related]
20. DNA methylation heterogeneity attributable to a complex tumor immune microenvironment prompts prognostic risk in glioma.
Ma S; Pan X; Gan J; Guo X; He J; Hu H; Wang Y; Ning S; Zhi H
Epigenetics; 2024 Dec; 19(1):2318506. PubMed ID: 38439715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]